Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,145 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Risk of developing psoriatic arthritis in psoriasis cohorts with arthralgia: exploring the subclinical psoriatic arthritis stage.
Zabotti A, Fagni F, Gossec L, Giovannini I, Sticherling M, Tullio A, Baraliakos X, De Marco G, De Vita S, Errichetti E, Quartuccio L, Silvagni E, Smolen JS, Tinazzi I, Watad A, Schett G, McGonagle DG, Simon D. Zabotti A, et al. Among authors: smolen js. RMD Open. 2024 Apr 10;10(2):e004314. doi: 10.1136/rmdopen-2024-004314. RMD Open. 2024. PMID: 38599649 Free PMC article.
Trends in Systemic Glucocorticoid Utilization in the United Kingdom from 1990 to 2019: A Population-Based, Serial Cross-Sectional Analysis.
Menzies-Gow AN, Tran TN, Stanley B, Carter VA, Smolen JS, Bourdin A, Fitzgerald JM, Raine T, Chapaneri J, Emmanuel B, Jackson DJ, Price DB. Menzies-Gow AN, et al. Among authors: smolen js. Pragmat Obs Res. 2024 Mar 15;15:53-64. doi: 10.2147/POR.S442959. eCollection 2024. Pragmat Obs Res. 2024. PMID: 38505738 Free PMC article.
Efficacy and safety of pharmacological treatment of psoriatic arthritis: a systematic literature research informing the 2023 update of the EULAR recommendations for the management of psoriatic arthritis.
Kerschbaumer A, Smolen JS, Ferreira RJO, Bertheussen H, Baraliakos X, Aletaha D, McGonagle DG, van der Heijde D, McInnes IB, Esbensen BA, Winthrop KL, Boehncke WH, Schoones JW, Gossec L. Kerschbaumer A, et al. Among authors: smolen js. Ann Rheum Dis. 2024 Mar 19:ard-2024-225534. doi: 10.1136/ard-2024-225534. Online ahead of print. Ann Rheum Dis. 2024. PMID: 38503473 Free article.
EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update.
Gossec L, Kerschbaumer A, Ferreira RJO, Aletaha D, Baraliakos X, Bertheussen H, Boehncke WH, Esbensen BA, McInnes IB, McGonagle D, Winthrop KL, Balanescu A, Balint PV, Burmester GR, Cañete JD, Claudepierre P, Eder L, Hetland ML, Iagnocco A, Kristensen LE, Lories R, Queiro R, Mauro D, Marzo-Ortega H, Mease PJ, Nash P, Wagenaar W, Savage L, Schett G, Shoop-Worrall SJW, Tanaka Y, Van den Bosch FE, van der Helm-van Mil A, Zabotti A, van der Heijde D, Smolen JS. Gossec L, et al. Among authors: smolen js. Ann Rheum Dis. 2024 Mar 18:ard-2024-225531. doi: 10.1136/ard-2024-225531. Online ahead of print. Ann Rheum Dis. 2024. PMID: 38499325 Free article.
Leveraging the holistic benefits of biosimilars in Europe - part 2: how payers can safeguard the future of a healthy biosimilar market environment.
Mestre-Ferrandiz J, Czech M, Smolen JS, Cornes P, Aapro MS, Danese S, Deitch S, Tyldsley H, Foster W, Shah P, Latymer M, Vulto AG. Mestre-Ferrandiz J, et al. Among authors: smolen js. Expert Rev Pharmacoecon Outcomes Res. 2024 Apr;24(4):509-519. doi: 10.1080/14737167.2024.2310684. Epub 2024 Feb 12. Expert Rev Pharmacoecon Outcomes Res. 2024. PMID: 38284223
1,145 results